entertainment -WSS

entertainment

author：focus 2025-09-27 09:58:32 - browse：24

In the center, three researchers examine a DNA helix. Two people stand in the front, one puts an apple into a capsule containing vegetables, the other holds a check list while standing next to a pile of medicines. On the right side, a scientist injects into mitochondria while another takes notes. A person behind the duo looks at a projection of a brain. On the left side, a client looks at a heart projection from a device held by a robot — biotech coverage from STAT — Adobe

When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.

But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.

The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Healthy food access boosts outcomes in two studies

WSS

Mayo Clinic plans $5B tech

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Will the market for weight loss drugs really reach $100 billion?

Weight loss drugs should be covered by insurers, AMA says

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Diagnostic tests are hitting their mathematical limits

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

After decades in use, heart stents finally beat placebo

Malaria cases in Florida and Texas: Here’s what you need to know

With clinical trial data readouts, here's how to spot spin

Medicare proposal to cover medical devices draws a mixed reaction

FDA reorg will put new emphasis on investigations, sources say

Medical leaders decry Supreme Court decision on affirmative action

Carbon Health diabetes program, a test of data

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

With clinical trial data readouts, here's how to spot spin

focus

Today's health inequities arise from racist U.S. history, say experts

J&J to emphasize cancer drugs, stop much of its vaccine research

Medicare’s new pay boost for primary care is angering specialists

Diagnostic tests are hitting their mathematical limits

Carbon Health diabetes program, a test of data

Today's health inequities arise from racist U.S. history, say experts

hotspot

hotspot

Wikipedia

focus